Goen Bio

Goen Bio is a South Korean biotechnology company focused on developing next-generation microbiome therapeutics. The company specializes in the research and mass production of Akkermansia muciniphila, a key gut bacterium associated with metabolic health. Goen Bio's pipeline targets prevalent conditions including obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH) by leveraging the bacterium's ability to strengthen the gut barrier and regulate metabolic pathways. Their proprietary technology platform enables the stable cultivation and formulation of anaerobic bacteria for clinical use. Founded by experts in microbial fermentation, the company aims to address chronic metabolic disorders through high-purity live biotherapeutic products.